Axcella Health, which is developing amino acid-based therapies to treat liver and other diseases, raised $71 million by offering 3.6 million shares at $20, the low end of the range of $20 to $22. Axcella Health plans to list on the Nasdaq under the symbol AXLA. Goldman Sachs, J.P. Morgan and SVB Leerink acted as lead managers on the deal.
